...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis - Influence on IP-10, TNF-α and MCP-1
【24h】

Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis - Influence on IP-10, TNF-α and MCP-1

机译：Telmisartan对冠状动脉粥样硬化患者炎症状态的影响 - 对IP-10，TNF-α和MCP-1的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Hypertension is one of the most prominent risk factors for coronary artery disease (CAD). Treatment of hypertension is therefore important for reducing cardiovascular events and the progression of atherosclerosis. Several treatment strategies are common in clinical practice for example the use of ACE-blockers or angiotensin receptor II blockers (ARBs), so called sartans. Telmisartan, belonging to the class of ARBs, was shown to exert anti-inflammatory effects besides the blood pressure lowering. Methods: In this work, two separate substudy groups of hypertensives were compared. 16 patients with arterial hypertension have been treated with telmisartan (initial 40. mg Kinzalmono?) for 7.3±4.4 months. The telmisartan group was compared to a matched control group including 31 hypertensive patients without telmisartan treatment with a follow up period of 1.9±0.5 years. Serum samples from the beginning and the end of follow up were analyzed with Luminex? technology for 26 cytokines and chemokines. The baseline scores of coronary artery calcification (CAC) were gathered by multislice detector computer tomography. Results: After 7. months of telmisartan treatment and 2. years in control patients most of the measured analytes did not change significantly. MCP-1 (P=0.001; P<0.001) was increased significantly in both telmisartan and control group. The relative decrease in IP-10 and TNF-α levels was observed in telmisartan group, as opposed to the increase in control (telmisartan vs. control P=0.048; P=0.01). No linear rank-correlation between measured analytes and the initial CAC was found. Conclusion: Telmisartan reduced blood pressure in patients with atherosclerosis and arterial hypertension within a short time period, whereas the inflammatory status of these patients remained largely unchanged. An involvement of telmisartan in the regulation of inflammatory and anti-inflammatory mediators in the context of CAD and CAC is possible, but cannot clearly be assumed based on the present findings.
机译：背景：高血压是冠状动脉疾病（CAD）最突出的危险因素之一。因此，高血压治疗对于减少心血管事件和动脉粥样硬化的进展是重要的。在临床实践中常见的几种治疗策略例如使用Ace-Dallacters或血管紧张素受体II阻断剂（ARB），所谓的Sartans。除了血压下降之外，属于ARB类的替代赛，属于ARB的类别。方法：在这项工作中，比较了两种分离的血容化血液化血容量。 16例动脉高压患者已用Telmisartan治疗（初始40.mg Kinzalmono？）治疗7.3±4.4个月。将Telmisartan组与匹配对照组进行比较，其中31例高血压患者没有替斯坦坦治疗，后续期为1.9±0.5岁。随后的开始和结束的血清样本进行了分析了Luminex？ 26种细胞因子和趋化因子的技术。冠状动脉钙化（CAC）的基线评分由多层探测器计算机断层扫描收集。结果：经过7.多年的Telmisartan治疗和2.年度控制患者的大多数测量分析物没有显着变化。在Telmisartan和对照组中，MCP-1（P = 0.001; P <0.001）显着增加。在替米沙尔坦组中观察到IP-10和TNF-α水平的相对降低，而不是对照的增加（Telmisartan对照P = 0.048; P = 0.01）。未发现测量分析物与初始CAC之间的线性秩相关。结论：Telmisartan在短时间内患有动脉粥样硬化和动脉高血压患者的血压降低，而这些患者的炎症状况在很大程度上保持不变。 Telmisartan在CAD和CAC背景下调节炎症和抗炎介质的调节中，但不能根据目前的研究结果清楚地假设。

著录项

  • 来源
    《Cytokine》 |2013年第2期|共7页
  • 作者

    KlinghammerL.; UrschelK.; CichaI.; LewczukP.; Raaz-SchrauderD.; AchenbachS.; GarlichsC.D.;

  • 作者单位

    Department of Cardiology and Angiology University Hospital Erlangen Germany;

    Department of Cardiology and Angiology University Hospital Erlangen Germany;

    Department of Cardiology and Angiology University Hospital Erlangen Germany;

    Department of Clinical Psychiatry University Hospital Erlangen Germany;

    Department of Cardiology and Angiology University Hospital Erlangen Germany;

    Department of Cardiology and Angiology University Hospital Erlangen Germany;

    Department of Cardiology and Angiology University Hospital Erlangen Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    Δa; Δ; Δa; Atherosclerosis; CAC; Chemokines; Cytokines; Risk factors; Telmisartan;

    机译：％Δa;δ;Δa;动脉粥样硬化;cac;趋化因子;细胞因子;风险因素;Telmisartan;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号